MA32713B1 - Anticorps anti-egfr/anti-igf-1r bispecifiques - Google Patents
Anticorps anti-egfr/anti-igf-1r bispecifiquesInfo
- Publication number
- MA32713B1 MA32713B1 MA33773A MA33773A MA32713B1 MA 32713 B1 MA32713 B1 MA 32713B1 MA 33773 A MA33773 A MA 33773A MA 33773 A MA33773 A MA 33773A MA 32713 B1 MA32713 B1 MA 32713B1
- Authority
- MA
- Morocco
- Prior art keywords
- igf
- bispecific antibodies
- egfr
- antibodies
- manufacture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
L'invention concerne des anticorps bispécifiques contre EGFR et contre IGF-1R, leurs procédés de fabrication, des compositions pharmaceutiques contenant lesdits anticorps et leurs utilisations.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08016952 | 2008-09-26 | ||
EP09004908 | 2009-04-02 | ||
PCT/EP2009/006782 WO2010034441A1 (fr) | 2008-09-26 | 2009-09-21 | Anticorps anti-egfr/anti-igf-1r bispécifiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32713B1 true MA32713B1 (fr) | 2011-10-02 |
Family
ID=41338633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33773A MA32713B1 (fr) | 2008-09-26 | 2011-04-13 | Anticorps anti-egfr/anti-igf-1r bispecifiques |
Country Status (18)
Country | Link |
---|---|
US (2) | US20100081796A1 (fr) |
EP (1) | EP2342231A1 (fr) |
JP (1) | JP2012503612A (fr) |
KR (1) | KR20110047255A (fr) |
CN (2) | CN102164960A (fr) |
AR (1) | AR073664A1 (fr) |
AU (1) | AU2009296297A1 (fr) |
BR (1) | BRPI0919382A2 (fr) |
CA (1) | CA2736408A1 (fr) |
CO (1) | CO6362023A2 (fr) |
EC (1) | ECSP11010913A (fr) |
IL (1) | IL211675A0 (fr) |
MA (1) | MA32713B1 (fr) |
MX (1) | MX2011003133A (fr) |
PE (1) | PE20110926A1 (fr) |
RU (1) | RU2011116112A (fr) |
TW (1) | TW201019960A (fr) |
WO (1) | WO2010034441A1 (fr) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7722867B2 (en) * | 2005-02-07 | 2010-05-25 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
AR062223A1 (es) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
WO2010040105A2 (fr) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Protéines de liaison multicibles antagonistes de cd86 |
UA105198C2 (ru) | 2008-12-12 | 2014-04-25 | Берингер Ингельхайм Интернациональ Гмбх | Антитело против инсулиноподобных факторов роста |
EP2414391B1 (fr) | 2009-04-02 | 2018-11-28 | Roche Glycart AG | Anticorps multispécifiques renfermant des anticorps complets et des fragments fab monocaténaires |
WO2010115589A1 (fr) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Anticorps trivalents bispécifiques |
AU2010252284A1 (en) * | 2009-05-27 | 2011-11-17 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2011028952A1 (fr) * | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes |
RU2573915C2 (ru) | 2009-09-16 | 2016-01-27 | Дженентек, Инк. | Содержащие суперспираль и/или привязку белковые комплексы и их применение |
EP2519544A1 (fr) * | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Hétérodimères polypeptidiques et leurs utilisations |
US20110200595A1 (en) * | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
GB201005064D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
CN102241774B (zh) * | 2010-05-27 | 2014-05-14 | 四川大学 | 重组IgE-Fc-抗EGFR单链抗体融合蛋白及其制备方法和用途 |
CA2802344C (fr) * | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques |
EP2596114A4 (fr) * | 2010-07-14 | 2014-01-08 | Amgen Inc | Immunoglobuline à insertion de domaine |
DK3029066T3 (da) | 2010-07-29 | 2019-05-20 | Xencor Inc | Antistoffer med modificerede isoelektriske punkter |
EP2609112B1 (fr) * | 2010-08-24 | 2017-11-22 | Roche Glycart AG | Anticorps bispécifique et activable |
WO2012025530A1 (fr) * | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Anticorps bispécifiques comprenant un fragment fv stabilisé par bisulfure |
US11066483B2 (en) * | 2010-11-30 | 2021-07-20 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
WO2012085111A1 (fr) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée |
KR101638224B1 (ko) | 2011-02-28 | 2016-07-08 | 에프. 호프만-라 로슈 아게 | 항원 결합 단백질 |
JP5768147B2 (ja) | 2011-02-28 | 2015-08-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 一価抗原結合タンパク質 |
EP2686348B1 (fr) * | 2011-03-17 | 2015-12-30 | Ramot at Tel-Aviv University Ltd. | Anticorps asymétriques, bispécifiques et monospécifiques et procédés de génération de ceux-ci |
EP2543680A1 (fr) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Fragment Fab d'anticorps multi-spécifiques mutés |
DK2748202T3 (en) * | 2011-08-23 | 2018-09-17 | Roche Glycart Ag | BISPECIFIC ANTI-BINDING MOLECULES |
CN104302668A (zh) * | 2011-09-23 | 2015-01-21 | 罗氏格黎卡特股份公司 | 双特异性的抗-egfr/抗igf-1r抗体 |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
WO2013059206A2 (fr) | 2011-10-17 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anticorps monoclonaux humains monospécifiques ou bispécifiques ciblant le facteur de croissance ii analogue à l'insuline (igf-ii) |
CA2850572A1 (fr) * | 2011-10-20 | 2013-04-25 | Esbatech, A Novartis Company Llc | Anticorps stable se liant a de multiples antigenes |
KR102398736B1 (ko) | 2011-10-31 | 2022-05-16 | 추가이 세이야쿠 가부시키가이샤 | 중쇄와 경쇄의 회합이 제어된 항원 결합 분자 |
BR112014019579A2 (pt) | 2012-02-10 | 2019-10-15 | Genentech, Inc | Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero |
CN104302664B (zh) * | 2012-03-14 | 2021-11-26 | 瑞泽恩制药公司 | 多特异性抗原结合分子及其用途 |
SI2833907T1 (en) * | 2012-04-06 | 2018-07-31 | Omeros Corporation | COMPOSITION AND METHODS OF INJECTION OF MASP-1 AND / OR MASP-3 FOR TREATMENT OF PAROXYSIMAL NIGHT CHEMOGLOBINURIA |
WO2013158856A2 (fr) | 2012-04-20 | 2013-10-24 | Emergent Product Development Seattle, Llc | Polypeptides se liant à cd3 |
US9944707B2 (en) | 2012-05-17 | 2018-04-17 | Sorrento Therapeutics, Inc. | Antibodies that bind epidermal growth factor receptor (EGFR) |
BR112014032193A2 (pt) | 2012-06-27 | 2017-06-27 | Hoffmann La Roche | métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico |
CA2871882A1 (fr) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Methode de fabrication de conjugues d'anticorps a region fc comprenant au moins une entite de liaison qui se lie specifiquement a une cible et leurs utilisations |
WO2014028221A1 (fr) | 2012-07-31 | 2014-02-20 | Crown Bioscience, Inc. | Marqueurs histologiques pour l'identification de patients atteints d'un carcinome du poumon non à petites cellules pour le traitement par un médicament anti-egfr |
DK2890712T3 (da) * | 2012-08-29 | 2019-07-08 | Hoffmann La Roche | Blod-hjerne-barriere-shuttle |
WO2014067642A1 (fr) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Procédé de fabrication d'anticorps plurispécifiques |
EP2727941A1 (fr) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Procédé pour la production d'anticorps multispécifiques |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
WO2014110601A1 (fr) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Nouvelles protéines hétérodimères |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US9738722B2 (en) | 2013-01-15 | 2017-08-22 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
CA2891493C (fr) | 2013-02-26 | 2022-03-15 | Roche Glycart Ag | Molecules de liaison a l'antigene bispecifiques activant des lymphocytes t |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
EP3421495A3 (fr) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation de cellules t avec des anticorps bispécifiques et des fusions fc |
CN103509117B (zh) * | 2013-05-06 | 2016-03-09 | 江苏匡亚生物医药科技有限公司 | 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途 |
JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
MX2016003593A (es) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. |
CR20160506A (es) | 2014-03-28 | 2017-03-10 | Xencor Inc | Anticuerpos biespecíficos que se unen a cd38 y cd3 |
CA2943943C (fr) | 2014-04-07 | 2023-01-10 | Chugai Seiyaku Kabushiki Kaisha | Molecule d'immunoactivation de liaison a un antigene |
CA2944402A1 (fr) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Navettes de la barriere hemato-encephalique contenant des anticorps reconnaissant l'alpha-synucleine |
KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201411420D0 (en) * | 2014-06-26 | 2014-08-13 | Ucb Biopharma Sprl | Antibody constructs |
AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CA2968878A1 (fr) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Anticorps heterodimeriques se liant aux antigenes cd3 et cd38 |
DK3223845T3 (da) | 2014-11-26 | 2021-08-16 | Xencor Inc | Heterodimere antistoffer, der binder cd3 og cd20 |
WO2016087416A1 (fr) * | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Anticorps multispécifiques |
EP3237449A2 (fr) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Anticorps trispécifiques |
US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
WO2016205784A1 (fr) * | 2015-06-19 | 2016-12-22 | The Scripps Research Institute | Procédés et compositions pour produire des cellules tueuses naturelles activées, et utilisations associées |
RS62986B1 (sr) | 2015-06-24 | 2022-03-31 | Hoffmann La Roche | Antitela na transferinski receptor sa prilagođenim afinitetom |
AU2016289480C1 (en) | 2015-07-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
JP7002446B2 (ja) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Cd3結合ポリペプチド |
TWI747843B (zh) | 2015-10-02 | 2021-12-01 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
EP3378488A4 (fr) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | Procédé pour renforcer la réponse immunitaire humorale |
WO2017086367A1 (fr) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | Polythérapie utilisant une molécule de liaison à l'antigène à rôle de redirection des cellules t, ciblant des cellules immunosupressives |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
SG11201803989WA (en) | 2015-12-28 | 2018-06-28 | Chugai Pharmaceutical Co Ltd | Method for promoting efficiency of purification of fc region-containing polypeptide |
US10344067B2 (en) * | 2016-02-25 | 2019-07-09 | Deutsches Krebsforschungszentrum | RNA viruses expressing IL-12 for immunovirotherapy |
US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
WO2017190079A1 (fr) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Procédés de production de molécules multispécifiques se liant à l'antigène |
WO2017218707A2 (fr) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Anticorps inhibiteurs de points de contrôle bispécifiques |
CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
JP7057360B2 (ja) * | 2016-08-29 | 2022-04-19 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | 抗-cd3抗体製剤 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP6785372B2 (ja) * | 2016-09-30 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性分子の機能分析のためのsprに基づく二重結合アッセイ |
JP7097354B2 (ja) * | 2016-10-05 | 2022-07-07 | アクセルロン ファーマ インコーポレイテッド | Tgf-ベータスーパーファミリーi型およびii型受容体ヘテロ多量体ならびにその使用 |
EP3526241A1 (fr) | 2016-10-14 | 2019-08-21 | Xencor, Inc. | Protéines de fusion fc hétérodimères il15/il15r |
CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
WO2019062755A1 (fr) * | 2017-09-29 | 2019-04-04 | Wuxi Biologics (Shanghai) Co., Ltd. | Anticorps bispécifiques dirigés contre egfr et pd-1 |
US11312770B2 (en) | 2017-11-08 | 2022-04-26 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
BR112020011875A2 (pt) * | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
CA3086199A1 (fr) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Proteines de fusion il-2 fc modifiees |
CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
US10982006B2 (en) | 2018-04-04 | 2021-04-20 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
WO2019204655A1 (fr) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Protéines de fusion hétérodimères ciblant tim-3 contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène de tim-3 |
JP2022503959A (ja) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | Il-12ヘテロ二量体fc-融合タンパク質 |
EP3930850A1 (fr) | 2019-03-01 | 2022-01-05 | Xencor, Inc. | Anticorps hétérodimères qui se lient à enpp3 et cd3 |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
AU2021329378A1 (en) | 2020-08-19 | 2023-03-23 | Xencor, Inc. | Anti-CD28 compositions |
CN117157319A (zh) | 2021-03-09 | 2023-12-01 | Xencor股份有限公司 | 结合cd3和cldn6的异二聚抗体 |
WO2022192586A1 (fr) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Anticorps hétérodimères qui se lient au cd3 et au gpc3 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2427964T3 (es) * | 2002-01-18 | 2013-11-05 | Pierre Fabre Medicament | Nuevos anticuerpos anti-IGF-IR y sus aplicaciones |
US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
US7579157B2 (en) * | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
JP2008512352A (ja) * | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
US7722867B2 (en) * | 2005-02-07 | 2010-05-25 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
AU2006318580A1 (en) * | 2005-11-21 | 2007-05-31 | Merck Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
-
2009
- 2009-09-21 BR BRPI0919382A patent/BRPI0919382A2/pt not_active IP Right Cessation
- 2009-09-21 AU AU2009296297A patent/AU2009296297A1/en not_active Abandoned
- 2009-09-21 CN CN2009801377233A patent/CN102164960A/zh not_active Withdrawn
- 2009-09-21 KR KR1020117006890A patent/KR20110047255A/ko not_active Application Discontinuation
- 2009-09-21 JP JP2011528222A patent/JP2012503612A/ja active Pending
- 2009-09-21 PE PE2011000643A patent/PE20110926A1/es not_active Application Discontinuation
- 2009-09-21 RU RU2011116112/10A patent/RU2011116112A/ru not_active Application Discontinuation
- 2009-09-21 MX MX2011003133A patent/MX2011003133A/es not_active Application Discontinuation
- 2009-09-21 WO PCT/EP2009/006782 patent/WO2010034441A1/fr active Application Filing
- 2009-09-21 EP EP09815644A patent/EP2342231A1/fr not_active Withdrawn
- 2009-09-21 CN CN2012100823052A patent/CN102643345A/zh active Pending
- 2009-09-21 CA CA2736408A patent/CA2736408A1/fr not_active Abandoned
- 2009-09-23 AR ARP090103662A patent/AR073664A1/es unknown
- 2009-09-23 TW TW098132098A patent/TW201019960A/zh unknown
- 2009-09-24 US US12/565,786 patent/US20100081796A1/en not_active Abandoned
-
2011
- 2011-03-10 IL IL211675A patent/IL211675A0/en unknown
- 2011-03-25 EC EC2011010913A patent/ECSP11010913A/es unknown
- 2011-03-30 CO CO11039189A patent/CO6362023A2/es not_active Application Discontinuation
- 2011-04-13 MA MA33773A patent/MA32713B1/fr unknown
- 2011-12-20 US US13/330,724 patent/US20120149879A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2010034441A1 (fr) | 2010-04-01 |
BRPI0919382A2 (pt) | 2016-01-05 |
CN102643345A (zh) | 2012-08-22 |
AR073664A1 (es) | 2010-11-24 |
CN102164960A (zh) | 2011-08-24 |
RU2011116112A (ru) | 2012-11-10 |
MX2011003133A (es) | 2011-04-21 |
ECSP11010913A (es) | 2011-08-31 |
TW201019960A (en) | 2010-06-01 |
CO6362023A2 (es) | 2012-01-20 |
CA2736408A1 (fr) | 2010-04-01 |
AU2009296297A1 (en) | 2010-04-01 |
EP2342231A1 (fr) | 2011-07-13 |
US20120149879A1 (en) | 2012-06-14 |
PE20110926A1 (es) | 2011-12-29 |
JP2012503612A (ja) | 2012-02-09 |
IL211675A0 (en) | 2011-06-30 |
US20100081796A1 (en) | 2010-04-01 |
KR20110047255A (ko) | 2011-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32713B1 (fr) | Anticorps anti-egfr/anti-igf-1r bispecifiques | |
MA38554A3 (fr) | Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation | |
MA33537B1 (fr) | Anticorps anti-cdcp1 humanisés | |
MA30497B1 (fr) | Anticorps et immunco-conjugues, et leurs utilisations. | |
MA33198B1 (fr) | Anticorps anti-her di-spécifiques | |
MA34172B1 (fr) | Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2 | |
MA32876B1 (fr) | Anticorps dirigés contre l'angiopoïétine 2 humaine | |
MA37538B1 (fr) | Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation | |
AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
MA30910B1 (fr) | Anticorps et immunoconjugues, et leurs utilisations | |
MA33551B1 (fr) | Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants | |
MA35724B1 (fr) | Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production. | |
AU2009301431A8 (en) | Bispecific anti-VEGF/anti-ANG-2 antibodies | |
EA200702329A1 (ru) | Замещенные пирролпиридины, содержащие их композиции, способ получения и применение | |
CO6571886A2 (es) | Antagonistas de pcsk9 | |
MA30531B1 (fr) | Anticorps anti-dll4 et leurs procedes d'utilisation | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
MA34722B1 (fr) | Méthodes et compositions pour l'immunothérapie de maladies neurales | |
MY161909A (en) | Anti-her3 antibodies and uses thereof | |
DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
MY158560A (en) | Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
WO2012088266A3 (fr) | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 | |
MX2014011818A (es) | Anticuerpos biespecificos contra inductor debil de la apoptosis relacionado con el tnf (tweak) humana e il17 humana y usos de los mismos. | |
MA35898B1 (fr) | Anticorps anti-lrp5 et leurs procédés d'utilisation |